Minipuberty of Infancy and the Timing of Pubertal Development in Adolescence: a Follow-up of the Infant Feeding and Early Development (IFED) Cohort

Inclusion Criteria

• •In order to be eligible to participate in this study, an individual must meet all of the following criteria:
• •1. Completion of the original IFED study, defined as participants who did not withdraw from the study or were not withdrawn by the investigator prior to the end of original follow-up (up to 7 months in males and 9 months in females) and who provided at least the minimum number of blood samples (3 for boys, 4 for girls) across the original study period (N=283 eligible families).
• •2. Ability of subject and mother to understand and the willingness to review informed assent and consent documents, respectively, and indicate agreement to participate.
• •Diagnoses/conditions:
• •Central or peripheral precocious puberty
• •Delayed puberty
• •Growth hormone deficiency
• •Stunted or delayed growth
• •Idiopathic short stature
• •Hypopituitarism
• •Thyroid conditions, such as hyperthyroid, hypothyroid, Graves disease, Hashimoto's thyroiditis
• •Genetic conditions, such as Prader-Willi syndrome, Turner syndrome, and Noonan syndrome
• •Medications:
• •Gonadotropin-Releasing Hormone Agonists (e.g., leuprolide acetate (Lupron Depot), triptorelin (Triptodur), histrelin implant (Supprelin LA))
• •Hormone therapy (e.g., testosterone, estrogen)
• •Synthetic human growth hormone or IGF-1
• •Synthetic thyroid hormone (e.g., levothyroxine)
• •Anti-thyroid medications (e.g., methimazole, propylthiouracil) or radioactive iodine treatment